A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)

Not Recruiting

Trial ID: NCT00250432,

Purpose

Comparison of the safety and effectiveness of standard drug dosing versus a daily dose 3 times higher than the standard dose in patients with invasive candidiasis (bloodstream and/or systemic yeast infections)

Official Title

A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of Caspofungin in the Treatment of Invasive Candidiasis in Adults

Stanford Investigator(s)

Wes (Janice) Brown
Wes (Janice) Brown

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Dora Ho
Dora Ho

Clinical Professor, Medicine - Infectious Diseases

Eligibility


Inclusion Criteria:

   - Clinical and Laboratory evidence of blood stream &/or systemic candida infections

Exclusion Criteria:

   - Possible candida contamination

   - Candida colonization (non invasive infection), urine, cardiac, bone or brain and
   prosthetic device infections

   - Acute or moderately severe liver disease

   - Abnormal liver function tests

   - Abnormal blood clotting for patients on blood thinners

Intervention(s):

drug: caspofungin acetate

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Joanna Schaenman

New Trial Alerts

Receive email alerts when trials open to patients.